

[Received by the International Bureau on 3 February 2005 (03.02.05);
original claims 1-14 replaced by amended claims 1-12]

1. An adjuvant comprising a surfactant and the apolar fraction or part of the apolar fraction of the total lipid extract of a mycobacterium, e.g. the BCG, *M. microti*, *M. tuberculosis* and *M. vaccae*.
2. An adjuvant according to claim 1 where the part of the apolar fraction of the lipid extract can be phthiocerol dimycocerosates, trehalose mycolipenates, glycosylated phenol phthiocerols (including phenolic glycolipids, PGL's), trehalose mycolates, sulfolipids, triacylglycerols or menaquinones
3. An adjuvant according to claim 1-2 where the surfactant is cationic.
4. An adjuvant according to claim 3 where the surfactant is DDA, DODA, DC-chol or DOTAP.
5. An adjuvant according to claim 1-2 where the surfactant is neutral or anionic, e.g. DOPE/PC or DOPE/PC/PG.
6. A vaccine comprising an adjuvant according to claim 1-5.
7. A vaccine according to claim 6 for parenterally, oral or mucosal administration.
8. A vaccine according to claim 7 where the antigenic component comprises an antigenic epitope from a virulent mycobacterium, e.g. *Mycobacterium tuberculosis*, *M. bovis* or *M. africanum*.
9. A vaccine according to claim 8 where the antigenic component is an ESAT6-Ag85B hybrid or a fragment hereof.
10. A vaccine according to claim 7 for treating cancer, allergy or autoimmune diseases.
11. A delivery system comprising an adjuvant according to claim 1-5.

12. Preparing an adjuvant according to claim 1-5 using thin lipid film method.